{"pmid":32354634,"pmcid":"PMC7142691","title":"A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","text":["A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.","Kidney Int","Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco","32354634"],"abstract":["The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality."],"journal":"Kidney Int","authors":["Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354634","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.04.002","keywords":["acute kidney injury","inflammation","tocilizumab","transplantation"],"e_drugs":["Hydroxychloroquine","tocilizumab","Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495273402368,"score":9.490897,"similar":[{"pmid":32317402,"title":"Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York.","text":["Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York.","BACKGROUND: The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes. METHODS: We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes. RESULTS: Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up. CONCLUSIONS: Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed.","J Am Soc Nephrol","32317402"],"abstract":["BACKGROUND: The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes. METHODS: We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes. RESULTS: Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up. CONCLUSIONS: Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed."],"journal":"J Am Soc Nephrol","date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317402","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1681/ASN.2020030375","keywords":["covid-19","epidemiology and outcomes","kidney transplantation","transplant outcomes"],"link_comment_in":"32345701","locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666138493647060993,"score":292.80988},{"pmid":32351040,"title":"COVID-19 in kidney transplant recipients.","text":["COVID-19 in kidney transplant recipients.","There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals.","Am J Transplant","Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P","32351040"],"abstract":["There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals."],"journal":"Am J Transplant","authors":["Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32351040","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15967","locations":["Caucasian","myalgia","Leukopenia"],"e_drugs":["Tacrolimus","Azithromycin","Hydroxychloroquine","Prednisone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495707512832,"score":289.64523},{"pmid":32354637,"pmcid":"PMC7142878","title":"COVID-19 infection in kidney transplant recipients.","text":["COVID-19 infection in kidney transplant recipients.","By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy.","Kidney Int","Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore","32354637"],"abstract":["By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy."],"journal":"Kidney Int","authors":["Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354637","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.03.018","keywords":["covid-19","sars-cov-2 infection","immunosuppression","kidney transplantation"],"locations":["London","hypoxia","ferritin"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Case Report"],"weight":1,"_version_":1666138495195807744,"score":263.70972},{"pmid":32301155,"title":"COVID-19 in solid organ transplant recipients: a single-center case series from Spain.","text":["COVID-19 in solid organ transplant recipients: a single-center case series from Spain.","The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 +/- 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-beta (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.","Am J Transplant","Fernandez-Ruiz, Mario","Andres, Amado","Loinaz, Carmelo","Delgado, Juan F","Lopez-Medrano, Francisco","San Juan, Rafael","Gonzalez, Esther","Polanco, Natalia","Folgueira, Maria Dolores","Lalueza, Antonio","Lumbreras, Carlos","Aguado, Jose Maria","32301155"],"abstract":["The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 +/- 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-beta (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients."],"journal":"Am J Transplant","authors":["Fernandez-Ruiz, Mario","Andres, Amado","Loinaz, Carmelo","Delgado, Juan F","Lopez-Medrano, Francisco","San Juan, Rafael","Gonzalez, Esther","Polanco, Natalia","Folgueira, Maria Dolores","Lalueza, Antonio","Lumbreras, Carlos","Aguado, Jose Maria"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301155","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15929","keywords":["covid-19","sars-cov-2","coronavirus","outcome","solid organ transplantation","treatment"],"locations":["Madrid","Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1666138494803640321,"score":263.49036},{"pmid":32471001,"title":"COVID-19 in elderly kidney transplant recipients.","text":["COVID-19 in elderly kidney transplant recipients.","The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate.","Am J Transplant","Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio","32471001"],"abstract":["The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate."],"journal":"Am J Transplant","authors":["Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32471001","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/ajt.16096","locations":["obese"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668167109982552064,"score":256.95737}]}